AstraZeneca: acquisition of Fusion completed
In its press release, the group explains that the transaction is part of its strategy to offer cancer patients better-targeted treatments, instead of chemotherapy and radiotherapy.
Radio-conjugates or radioligands (RLTs) are innovative therapies currently under investigation, designed to bind specifically to over-expressed targets in tumors and cure difficult-to-treat cancers.
Under the terms of the transaction, Fusion will be delisted from the Nasdaq and become a wholly-owned subsidiary of AstraZeneca, with operations in both Canada and the USA.
The total acquisition price is estimated at some $2.4 billion.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction